|Mr. James J. Fiedler||Chairman & CEO||N/A||N/A||1947|
|Mr. Robert Gardiner||Pres & Director||N/A||N/A||N/A|
|Sukhinder Kalsi||CFO & Director||N/A||N/A||N/A|
|Mr. Mark Perkell||VP and Gen. Counsel||N/A||N/A||N/A|
|Dr. Allen Greenspoon M.D.||VP & Director||N/A||N/A||1954|
|Dr. Jasbir S. Kang M.D.||Treasurer, Sec. & Director||N/A||N/A||N/A|
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines to improve and optimize life. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The company was formerly known as CeCors, Inc. and changed its name to Psykey, Inc. in August 2021. Psykey, Inc. was founded in 2002 and is based in Toronto, Canada.
Psykey, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.